Metabolic Syndrome after Hematopoietic Cell Transplantation

At the Intersection of Treatment Toxicity and Immune Dysfunction

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Hematopoietic cell transplantation (HCT) survivors face a multitude of short- and long-term health complications in the years after treatment. One important health complication that is associated with significant morbidity is metabolic syndrome (MetSyn). This constellation of findings, which includes obesity, glucose and lipid dysmetabolism, and hypertension, places affected individuals at increased risk for type 2 diabetes mellitus, cardiovascular complications, and stroke. Previous studies have linked MetSyn in HCT survivors to prior treatment; however, few studies have addressed the potential roles of systemic inflammation and immune system dysfunction after HCT. Within this review, we address the recent advances in the understanding of adipose tissue biology, immune, and inflammatory mechanisms involved in MetSyn in non-HCT patients, and lastly, we discuss potential novel mechanisms that may play a role in MetSyn development after HCT, such as hematopoietic stem cell source, inflammatory status of the stem cell donor, and microbiome composition, all of which represent potential new directions for post-HCT MetSyn research.

Original languageEnglish (US)
Pages (from-to)1159-1166
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume22
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Cell Transplantation
Survivors
Therapeutics
Microbiota
Health
Hematopoietic Stem Cells
Type 2 Diabetes Mellitus
Adipose Tissue
Immune System
Stem Cells
Obesity
Myocardial Infarction
Tissue Donors
Hypertension
Inflammation
Morbidity
Lipids
Glucose
Research

Keywords

  • Hematopoietic cell transplantation
  • Late effects
  • Metabolic syndrome
  • Survivor

Cite this

@article{aec851387c7145cf8e9103db17f01b49,
title = "Metabolic Syndrome after Hematopoietic Cell Transplantation: At the Intersection of Treatment Toxicity and Immune Dysfunction",
abstract = "Hematopoietic cell transplantation (HCT) survivors face a multitude of short- and long-term health complications in the years after treatment. One important health complication that is associated with significant morbidity is metabolic syndrome (MetSyn). This constellation of findings, which includes obesity, glucose and lipid dysmetabolism, and hypertension, places affected individuals at increased risk for type 2 diabetes mellitus, cardiovascular complications, and stroke. Previous studies have linked MetSyn in HCT survivors to prior treatment; however, few studies have addressed the potential roles of systemic inflammation and immune system dysfunction after HCT. Within this review, we address the recent advances in the understanding of adipose tissue biology, immune, and inflammatory mechanisms involved in MetSyn in non-HCT patients, and lastly, we discuss potential novel mechanisms that may play a role in MetSyn development after HCT, such as hematopoietic stem cell source, inflammatory status of the stem cell donor, and microbiome composition, all of which represent potential new directions for post-HCT MetSyn research.",
keywords = "Hematopoietic cell transplantation, Late effects, Metabolic syndrome, Survivor",
author = "Turcotte, {Lucie M} and Ashley Yingst and Verneris, {Michael R}",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/j.bbmt.2016.03.016",
language = "English (US)",
volume = "22",
pages = "1159--1166",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Metabolic Syndrome after Hematopoietic Cell Transplantation

T2 - At the Intersection of Treatment Toxicity and Immune Dysfunction

AU - Turcotte, Lucie M

AU - Yingst, Ashley

AU - Verneris, Michael R

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Hematopoietic cell transplantation (HCT) survivors face a multitude of short- and long-term health complications in the years after treatment. One important health complication that is associated with significant morbidity is metabolic syndrome (MetSyn). This constellation of findings, which includes obesity, glucose and lipid dysmetabolism, and hypertension, places affected individuals at increased risk for type 2 diabetes mellitus, cardiovascular complications, and stroke. Previous studies have linked MetSyn in HCT survivors to prior treatment; however, few studies have addressed the potential roles of systemic inflammation and immune system dysfunction after HCT. Within this review, we address the recent advances in the understanding of adipose tissue biology, immune, and inflammatory mechanisms involved in MetSyn in non-HCT patients, and lastly, we discuss potential novel mechanisms that may play a role in MetSyn development after HCT, such as hematopoietic stem cell source, inflammatory status of the stem cell donor, and microbiome composition, all of which represent potential new directions for post-HCT MetSyn research.

AB - Hematopoietic cell transplantation (HCT) survivors face a multitude of short- and long-term health complications in the years after treatment. One important health complication that is associated with significant morbidity is metabolic syndrome (MetSyn). This constellation of findings, which includes obesity, glucose and lipid dysmetabolism, and hypertension, places affected individuals at increased risk for type 2 diabetes mellitus, cardiovascular complications, and stroke. Previous studies have linked MetSyn in HCT survivors to prior treatment; however, few studies have addressed the potential roles of systemic inflammation and immune system dysfunction after HCT. Within this review, we address the recent advances in the understanding of adipose tissue biology, immune, and inflammatory mechanisms involved in MetSyn in non-HCT patients, and lastly, we discuss potential novel mechanisms that may play a role in MetSyn development after HCT, such as hematopoietic stem cell source, inflammatory status of the stem cell donor, and microbiome composition, all of which represent potential new directions for post-HCT MetSyn research.

KW - Hematopoietic cell transplantation

KW - Late effects

KW - Metabolic syndrome

KW - Survivor

UR - http://www.scopus.com/inward/record.url?scp=84969551370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969551370&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2016.03.016

DO - 10.1016/j.bbmt.2016.03.016

M3 - Review article

VL - 22

SP - 1159

EP - 1166

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 7

ER -